Traffic Roots Audience Pixel PathogenDx | Board of Advisors

REGGIE GAUDINO, Ph.D.
Chief Scientific Advisor 
President, Steep Hill Labs, Inc.

 

Dr. Reggie Gaudino oversees all scientific research and development for Steep Hill and manages the YnsightTM genetics division. Dr. Gaudino directed a team of researchers which led to the development of GenKitTM, the first cannabis DNA-based sex test. The research from Dr. Gaudino has been peer-reviewed and published, leading to important new discoveries in the cannabis industry. He is internationally recognized as a leader in the field of cannabis genetics where his former experience as a Patent Agent with Sequenom brings valuable insight to the cannabis industry. His groundbreaking work was featured in April 2016 in Wired Magazine http://www.wired.com/2016/04/the-science-of-marijuana/.

Dr. Gaudino also is the Scientific Advisor for the partner company, PathogenDx, where he helps identify and commercialize DNA based testing opportunities in the Cannabis Industry. Dr. Gaudino and Steep Hill act as the partner laboratory for PathogenDx product development and validation testing. Dr. Gaudino also is currently advising additional Cannabis companies, from both a scientific and intellectual property perspective.

Dr. Gaudino received his B.S. in Molecular Biology and Ph.D. in Molecular Genetics from the State University of New York at Buffalo, and he conducted four years of post-doctoral research at the Washington University in St. Louis, studying transcriptional regulation of rRNA. Reggie was one of the first African-American molecular biologists to enter a Ph.D. program in the United States in 1985.

NEAL PATEL 

Principal 

Tendaji Ventures 

Neal Patel is a healthcare and biotechnology entrepreneur in both the Pharmaceutical and the Cannabis marketplace. Patel founded his first clinical diagnostics company, at the age of 23. Armed with a passion for enhancing the accessibility to healthcare for disparate communities, Patel later launched a private R&D Laboratory, responsible for engineering disruptive, cost-effective diagnostic tests. In 2017, Patel began establishing a stronghold for himself in the Pharmaceutical industry when he founded a private research entity that focuses on taking non-FDA Approved medications to market. In 2018 Patel became a prolific investor in several cannabis-focused entities and began establishing a strong foothold for himself in the cannabis industry. Patel now serves as Founder and Principal of Tendaji Ventures, an entity which allows Patel to exercise his ability to mature the cannabis market through strategic partnerships and alliances, either as an adviser or as an investor.